Kv1.3 Therapeutics Presents New, Published Data in Myositis Demonstrating the Presence of Kv1.3 Channels at the Site of the Muscle Damage Caused by Autoimmune Inflammatory Response

Home > Press Release > Kv1.3 Therapeutics Presents New, Published Data in Myositis Demonstrating the Presence of Kv1.3 Channels at the Site of the Muscle Damage Caused by Autoimmune Inflammatory Response

Kv1.3 Therapeutics Presents New, Published Data in Myositis Demonstrating the Presence of Kv1.3 Channels at the Site of the Muscle Damage Caused by Autoimmune Inflammatory Response

Data presented at the 22nd International Congress of the World Muscle Society suggests possible role for Dalazatide as a therapy in Myositis.

October 19, 2017. Seattle, Washington — Kv1.3 Therapeutics Inc., a Seattle-based, clinical stage biopharmaceutical company, today announced new data demonstrating the abundance of Kv1.3 channels in the muscle tissue of patients with sporadic Inclusion Body Myositis (sIBM). This data was presented at the 22nd International Congress of the World Muscle Society in France earlier this month and was also published as an abstract in Neuromuscular Disorders, the official journal of the World Muscle Society. D. Tahseen Mozaffar, Professor of Neurology at the University of California at Irvine presented the results. Dr. Mozaffar reported that these data show that patients with inclusion body myositis (IBM) demonstrated high Kv1.3 expression on effector memory T cells. These findings suggest that a drug like Kv1.3 Therapeutics’ dalazatide, which has been shown to be a potent and selective blocker of Kv1.3 channels, may have a role in controlling IBM and other myositis diseases.

Inclusion Body Myositis is an insidious degenerative autoimmune disease which is estimated to affect over 16,000 people in the US. The number of people affected by this disease is expected to increase over the next decades with some estimates suggesting that it will double by 2030. Currently no drugs are FDA approved for this disease and the majority of the patient management is focused on supportive care.

Link to Poster

Link to Abstract

About Dalazatide
Dalazatide is a novel Kv1.3 blocker, a first-in-class drug being developed initially for rare autoimmune diseases including as a potential treatment of myositis – a rare autoimmune disease with significant unmet medical need. Dalazatide is the lead drug in Kv1.3 Therapeutics’ patent-protected family of Kv1.3 blockers and has demonstrated activity in a variety of autoimmune disease models and a proof-of-concept prototypical Phase 1b clinical trial. In addition to showing clinical activity in a patient population, studies have also reinforced the immune sparing features of this drug. Kv1.3 Therapeutics, Inc.’s products provide potentially breakthrough solutions in the toolkit for physicians managing patients with rare and debilitating autoimmune diseases.

About Kv1.3 Therapeutics Inc.
Kv1.3 Therapeutics is a Seattle-based, clinical stage biopharmaceutical company. The company is committed to transforming treatment alternatives for patients with rare and autoimmune diseases. Kv1.3 Therapeutics is focused on developing a unique group of Kv1.3 blockers for potential management of rare diseases such as myositis, a rare and debilitating disease which affects over 16,000 Americans. Kv1.3 Therapeutics actively collaborates with private, academic and industry partners to advance research and clinical activities in rare diseases. For more information please visit us at Kv13Therapeutics.com.

Contact
For more information please contact us at info@kv13therapeutics.com or at 206-812-1405.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kv1.3 Therapeutics, Inc.’s plans for pre-clinical and clinical studies, regulatory filings, anticipated drug effects in human subjects, business performance and investment performance. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kv1.3’s business which could significantly affect expected results. All forwardlooking statements are qualified in their entirety by this cautionary statement, and Kv1.3 undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.